Aptevo Therapeutics Inc
$ 4.18
2.70%
07 Aug - close price
- Market Cap 5,208,700 USD
- Current Price $ 4.18
- High / Low $ 4.20 / 4.10
- Stock P/E N/A
- Book Value 9.65
- EPS 1488.13
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.18 %
- ROE -5.18 %
- 52 Week High 45.90
- 52 Week Low 3.68
About
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
Analyst Target Price
$25.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-20 | 2025-11-06 | 2025-08-11 | 2025-05-15 | 2025-03-04 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-05 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -6.41 | -5.9108 | -40.14 | -151.2 | -4.39 | -3218.4 | -6393.6 | -22244.4 | -132534.03 | -6.16 | -293039.71 | -720877.68 |
| Estimated EPS | -5.6 | -8.09 | -37.62 | -1497.6 | -4.21 | -2790 | -7592.4 | -25707.61 | -171095.43 | -18.04 | -439559.56 | -656408.94 |
| Surprise | -0.81 | 2.1792 | -2.52 | 1346.4 | -0.18 | -428.4 | 1198.8 | 3463.21 | 38561.4 | 11.88 | 146519.85 | -64468.74 |
| Surprise Percentage | -14.4643% | 26.937% | -6.6986% | 89.9038% | -4.2755% | -15.3548% | 15.7895% | 13.4715% | 22.5379% | 65.8537% | 33.3333% | -9.8214% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -6.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APVO
2026-08-08 13:09:57
Aptevo Therapeutics Inc (APVO) has an earnings forecast score of 8.00, ranking 171st in the Biotechnology & Medical Research industry. Analysts project an average price target of $420.00 for the stock, with one analyst recommending a "Buy" rating. The company's EPS for the previous quarter was -$6.23, beating the market expectation of -$6.41, and the next quarter's EPS is expected to be -$6.01.
2026-08-05 13:09:57
APVO (Aptevo Therapeutics Inc.) is scheduled to release its Q2'26 earnings on August 06, with an estimated EPS of (6.01) USD and revenue of 0 USD. The article provides a table of historical and estimated revenue and EPS figures, highlighting past EPS surprises. The announcement is expected at 8:00 AM ET (12:00 PM UTC).
2026-07-31 21:41:44
This article reports on an SEC filing made by Aptevo Therapeutics Inc. (APVO) on July 31, 2026. The filing, categorized as ARS, was accepted by the SEC EDGAR system at 4:05 PM on that date. The article also provides a brief overview of Aptevo Therapeutics, including its market cap, float, industry, sector, and recent news and SEC filings.
2026-07-31 12:11:33
Aptevo Therapeutics announced a new solid tumor strategy supported by a patent filing for a Nectin-4 x PD-L1 dual-targeting backbone. This platform aims to develop multiple therapeutic approaches, including radiopharmaceuticals and T-cell engagers, to fight solid tumors more effectively. The strategy focuses on precise tumor targeting and enhancing anti-tumor immunity by addressing both Nectin-4 on tumor cells and PD-L1 on immune-suppressing cells.
2026-07-31 08:41:19
This article provides a valuation analysis of Aptevo Therapeutics Inc (APVO), noting its current valuation score of 8.97 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio and mentions that relevant data for P/B and P/CF ratios have not yet been disclosed by the company. The stock closed at 4.110 USD with a market cap of 6.24 million.
2026-07-30 11:11:18
Aptevo Therapeutics Inc. (APVO) is scheduled to release its Q2'26 earnings on August 6th, with an anticipated revenue estimate of $0 and an EPS of ($6.01). The article provides a table summarizing past and estimated revenue and EPS figures, noting significant EPS surprises in previous quarters.
